Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week rangemarketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s following its government pricing deal announcementmarketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However, disappointing industry news and the uncertainty of the Metsera takeover battle led to profit-taking. By early November, Pfizer’s 50-day average converged with its 200-day averagemarketbeat.com, indicating a lack of a strong trend. This technical “flatline” suggests the stock is searching for direction, consolidating after its volatile swings.
